In light of these experimental pieces of evidence and the recently reported prognostic significance of serum sCXCL16 in ACS patients, shown in the PLATO trial [22], the current investigation expands our previous observation on the platelet CXCL16–CXCR6 axis and explores its translational implication in a cohort of n = 240 CAD patients. This evidence concerns the gene CXCR6 and coronary artery disorder.